Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with chemotherapy within its marketing authorisation for treating recurrent, persistent or metastatic cervical cancer.
 
Status In progress
Process STA 2018
ID number 3798

Provisional Schedule

Expected publication 23 November 2022

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
19 November 2021 Please note that following on from information received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-January 2022 when we will write to consultees and commentators about how they can get involved.
25 January 2021 The Department for Health and Social Care has asked NICE to conduct an appraisal of pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-June 2021 when we will write to you about how you can get involved. These timelines are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive submission.
02 October 2020 - 30 October 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 June 2020 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance